

RESEARCH ARTICLE

Open Access



# Oestradiol levels and superoxide dismutase activity in age-related cataract: a case-control study

Dragana Škiljić<sup>1,2\*</sup>, Staffan Nilsson<sup>3</sup>, Anne Petersen<sup>1</sup>, Jan-Olof Karlsson<sup>4</sup>, Anders Behndig<sup>5</sup>, Lada Kalaboukhova<sup>2</sup> and Madeleine Zetterberg<sup>1,2</sup>

## Abstract

**Background:** It has been suggested that the higher prevalence of cataract in women is caused by a withdrawal effect of oestrogen at menopause. In vitro studies have demonstrated protection of serum oestradiol (E2) against oxidative stress through upregulation of antioxidant enzymes, including superoxide dismutase (SOD). The purpose of the present study was to investigate E2 levels and SOD erythrocyte activity in patients with age-related cataract.

**Methods:** The studied subjects consisted of 103 patients with age-related cataract and 22 controls. Cataracts were classified as nuclear, cortical, or posterior subcapsular. Blood samples were collected and data on smoking, hormonal use, diabetes and age at menarche/menopause was obtained for all individuals. Serum oestradiol analyses were performed with radioimmunoassay (RIA) and SOD activity was measured in erythrocyte lysates.

**Results:** A negative correlation between age and E2 concentration was seen in a linear regression analysis. No correlation was seen between SOD activity and age or gender and no correlation between E2 levels and SOD activity was found using multiple linear regression. The mean level of E2 for all male subjects was  $50.1 \pm 16.3$  pmol/L, significantly higher compared to  $13.8 \pm 11.8$  pmol/L for postmenopausal women.

**Conclusion:** The present study does not support a role for E2-induced effects on SOD in cataract formation. The findings of higher E2 levels in men than in postmenopausal women may suggest that decreased oestrogen at menopause is partially responsible for the gender-related difference in cataract prevalence. However, the latter can only be verified through prospective randomized trials using hormonal replacement therapy.

**Keywords:** Age-related cataract, Gender, Oestradiol, Superoxide dismutase, Oxidative stress

## Background

Cataract is the most common cause of blindness in the world and as lifespan is getting longer, an increased number of people requiring cataract surgery can be anticipated. Several studies report higher prevalence of lens opacities in women as compared to men of the same age

[1–3]. It has been proposed that with the dramatic reduction in oestradiol levels in women entering menopause, the potentially protective effects of oestrogen are withdrawn, resulting in increased risk of cataract in women. Studies have shown that earlier menarche and later menopause, causing an extended period of reproductive years, are associated with lower risk of cataract and that the use of exogenous oestrogens, *i.e.* hormonal replacement therapy (HRT), is associated with decreased risk of cataract. It has therefore been suggested that oestrogen may protect against cataract. The Blue Mountain Eye study reported that current HRT users had

\* Correspondence: dragana.skiljic@gu.se

<sup>1</sup>Department of Clinical Neuroscience/Ophthalmology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

<sup>2</sup>Department of Ophthalmology, Sahlgrenska University Hospital, Mölndal, Sweden

Full list of author information is available at the end of the article



lower risk of developing cortical cataract and this was also confirmed in the follow-up study [4]. Current and longer use of HRT showed lower incidence of nuclear lens opacities in both the Beaver Dam Eye Study and the Framingham Eye Study cohort [5, 6].

Oxidative stress is a key factor in cataract formation. The major oestrogen, oestradiol (E2), has been ascribed antioxidant properties and several studies have shown oestrogen-mediated protection against oxidative stress through upregulation of antioxidant enzymes including superoxide dismutase (SOD) [7–9]. In addition, lens epithelial cells have also shown increased SOD activity after exposure to E2 [10]. Therefore, the purpose of the present study was to investigate possible correlations between SOD activity and E2 levels in patients with age-related cataract and controls.

## Methods

### Patients

Patients with age-related cataract and controls were recruited from the Eye Clinic at Sahlgrenska University Hospital/Mölndal, after informed consent. The Regional Research Ethics Committee in Gothenburg approved the study and the tenets of the Declaration of Helsinki were followed. The studied subjects consisted of 103 patients with age-related cataract and 22 controls. Cataracts were classified as nuclear, cortical, or posterior subcapsular using biomicroscopy performed by four different surgeons. Patients with secondary cataracts, such as steroid-induced cataract, were excluded. Controls were either spouses or relatives to glaucoma patients, had glaucoma themselves or were recruited from the emergency ophthalmic clinic, with diagnoses such as vitreous detachment or blepharitis. Exclusion criteria for controls were previous cataract surgery, age <60 years or current lens opacities. The latter was evaluated by slit lamp biomicroscopy by one ophthalmologist only. Data on smoking (current/former smoking habits), hormones (current/former use of contraceptives and/or hormone replacement therapy), diabetes and age at menarche/menopause was obtained for all individuals and age was reported at the time of sample collection (Table 1).

### Blood sampling

Venous blood samples were drawn from patients and controls and collected using tubes with anticoagulant (EDTA) for whole blood samples and tubes with clot activator and gel separator for serum samples (VACU-ETTE, Greiner Bio-One, Kremsmünster, Austria). The whole blood samples were handled the same day and erythrocytes were collected after centrifugation at  $800 \times g$  for 10 min at 4 °C. The erythrocytes were then lysed in four times its volume of ice-cold distilled water after which the samples were centrifuged at  $10.000 \times g$  for

**Table 1** Demographics of studied patients with age-related cataract and controls

Parameter	Cataract	Controls	<i>p</i> -value
Age (years)	<i>n</i> = 103 71 ± 10.9	<i>n</i> = 22 70 ± 3.4	0.35
Sex	<i>n</i> = 103	<i>n</i> = 22	
Female	61 (59.2)	16 (72.7)	0.24
Male	42 (40.8)	6 (27.3)	
Type of lens opacity <sup>a</sup>	<i>n</i> = 100		
Nuclear	93 (93.0)	-	-
Cortical	42 (42.0)	-	
Posterior subcapsular	23 (23.0)	-	
Mixed cataract	<i>n</i> = 102		
Yes	51 (50.0)	-	-
No	51 (50.0)	-	
Diabetes	<i>n</i> = 103	<i>n</i> = 22	
Yes	20 (19.4)	-	0.02
No	83 (80.6)	22 (100)	
Smoking	<i>n</i> = 103	<i>n</i> = 22	
Current smoker	19 (18.4)	1 (4.5)	0.11
Ever smoker <sup>b</sup>	69 (67.0)	12 (54.5)	0.27
Hormonal status	<i>n</i> = 102	<i>n</i> = 18	
Currently on hormones	9 (8.8)	3 (16.7)	0.31
Ever on hormones <sup>b</sup>	43 (42.2)	11 (61.1)	0.14
Menarche / Menopause			
Age at menarche	<i>n</i> = 57 13 ± 1.3	<i>n</i> = 12 13 ± 1.4	0.64
Age at menopause	<i>n</i> = 50 49 ± 6.8	<i>n</i> = 13 50 ± 3.6	0.49
Years in menopause <sup>c</sup>	<i>n</i> = 50 24 ± 11.7	<i>n</i> = 13 20 ± 5.8	0.16
Reproductive years	<i>n</i> = 48 35 ± 6.9	<i>n</i> = 12 38 ± 3.2	0.27

Data presented as absolute numbers (%) or mean ± SD. *P*-values were calculated with Pearson's chi-square test for categorical parameters and Student's *t*-test for continuous parameters

<sup>a</sup> Both eyes included. Many individuals had more than one subtype, *i.e.*

mixed cataract

<sup>b</sup> Includes former and current users

<sup>c</sup> Years in menopause prior to sampling

15 min at 4 °C and erythrocyte lysate was collected. The serum sample tubes were centrifuged at  $1800 \times g$  for 10 min after coagulation, within 3 h after sampling. Both aliquots of serum and erythrocyte lysate were stored at -80 °C until assayed.

### Oestradiol levels

Serum oestradiol analyses were performed with radio-immunoassay (Spectria Estradiol RIA, Orion Diagnostica,

Espoo, Finland) with an extraction step prior to quantification, yielding a sensitivity of 4 pmol/L, previously described by Ankarberg-Lindberg et al. [11]. The assay measures total oestradiol (17β-oestradiol) serum concentrations *i.e.* both free E2 and E2 previously bound to sex hormone-binding globulin (SHBG) or albumin.

**Total superoxide dismutase activity**

SOD activity was measured in erythrocyte lysate samples using the Superoxide Dismutase Assay kit, according to the manufacturer’s protocol (Cayman Chemical Company, Ann Arbor, MI, USA). Absorbance was measured at 440 nm on the microplate reader Infinite M200 PRO (Tecan group Ltd., Männedorf, Switzerland) using 96-well microplates (Greiner Bio-One, Kremsmünster, Austria). The SOD assay uses tetrazolium salt to detect superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit (U) of SOD is defined as the amount of enzyme needed to execute 50% dismutation of the superoxide radical. The assay measures total SOD activity per millilitre erythrocyte lysate (U/ml).

**Statistical analysis**

Demographic differences between cataract patients and control subjects were analysed using Student’s *t*-test for continuous parameters and Pearson’s chi-square test for categorical parameters (Table 1). Multiple linear regression was used to analyse potential predictors of the dependent variables; E2 levels and SOD activity. In the initial multivariate analysis, cataract type, smoking, diabetes, age at menarche/menopause and hormonal status were included, but since they showed no statistical significance they were excluded in the final model. Statistical analyses were performed using IBM SPSS Statistics 21.0 (IBM Corp., Armonk, NY, USA) and *p*-values ≤0.05 were considered statistically significant.

**Results**

There were no differences between the cataract and control group in demographic data except for a significantly higher frequency of diabetes in cataract patients compared to the control group (Table 1). Men had significantly higher E2 levels compared to postmenopausal women (*p* < 0.001); the mean level for men in both the cataract and control group (*i.e.* all subjects) was 50.1 ± 16.3 pmol/L compared to 13.8 ± 11.8 pmol/L for postmenopausal women, thus a considerable difference. E2 levels and SOD activity for the cataract and control group are shown in Table 2, with men and women presented separately. A negative correlation between age and E2 levels was seen in a linear regression analysis (Fig. 1). The higher E2 levels in men compared to postmenopausal women are also evident from the figure. Multivariate analysis showed significant impact of both

**Table 2** Concentrations of oestradiol (E2) in serum and superoxide dismutase (SOD) activity in erythrocytes in patients with age-related cataract and controls

	Cataract		Controls	
	Men	Women	Men	Women
	<i>n</i> = 37	<i>n</i> = 42	<i>n</i> = 6	<i>n</i> = 16
Oestradiol levels (pmol/L) <sup>a</sup>	50.7 ± 17.2	15.4 ± 13.0	46.0 ± 9.0	9.6 ± 6.6
	<i>n</i> = 41	<i>n</i> = 60	<i>n</i> = 6	<i>n</i> = 16
SOD activity (U/ml)	4.1 ± 0.9	4.1 ± 1.0	3.9 ± 1.2	4.2 ± 1.0


Data presented as mean ± SD

<sup>a</sup> Oestradiol (17β-oestradiol) levels measured in serum are only presented for postmenopausal women


age (*p* = 0.021) and sex (*p* < 0.001) on E2 levels, but not with cataract diagnosis. No correlation between SOD activity and E2 levels was found, using a multiple linear regression analysis with age, gender and diagnosis as covariates and the SOD-plate as a fixed factor in the model (Fig. 2). No predictors showed significant impact on SOD activity.

**Discussion**

The main sources of circulating oestrogen are the ovaries and testes in premenopausal non-pregnant women and men, respectively. Extragonadal production, like in adipose tissue, is also of physiologic importance as source of oestrogen in both men and postmenopausal women. In the ovaries and testes, oestrogens are biosynthesized from cholesterol and testosterone respectively whereas in extragonadal sites oestrogens are derived from androgenic precursors such as dehydroepiandrosterone



**Fig. 1** A negative correlation between age and serum oestradiol (E2) levels was seen in cataract patients and controls with linear regression analysis. Higher levels of serum E2 levels were evident in men compared to postmenopausal women



(DHEA), androstenediol and androstenedione, which can be converted into testosterone. Oestradiol (E2) is then biosynthesized through aromatization of testosterone and subsequently bound to sex hormone-binding globulin (SHBG) or albumin. Only a small fraction of E2 circulates free and unbound in the blood. E2 is the predominant oestrogen during the reproductive years in women and a dramatic decrease in E2 levels is seen in women entering menopause [12].

We observed significantly higher E2 levels in men compared to postmenopausal women. It has previously been reported that serum E2 levels can be higher in older men than in older women due to higher levels of testosterone and DHEA in men, resulting in higher E2 through peripheral aromatization [13, 14]. The reduction of E2 in women in menopause is thus not only dramatic, it even drops below the E2 concentration in men, something that may explain the increased prevalence of cataract in women. This hypothesis is further supported by studies on HRT and risk of cataract in women, showing protective effects of exogenously added oestradiol in postmenopausal women [4–6]. In addition, a large epidemiological study on prostate-cancer patients demonstrated higher incidence of cataract in those treated with androgen deprivation therapy, which lowers testosterone levels and consequently also decreases the production of E2 [15]. Oestradiol has been identified in the aqueous humour of humans, but the investigators did not find any differences between cataract patients and controls nor between men and women, when measuring E2 levels in aqueous humour [16]. Regarding the potential protective

effects of oestradiol on cataract formation, a possible upregulation of SOD has been suggested in *in vitro* experiments and in animal models [7, 8]. The present study is the first to actually investigate a possible correlation between oestradiol concentration and SOD activity in humans. However, in this study no such correlation could be found in cataract patients or in controls. Alternative explanations for the protective role of oestradiol may be scavenging of reactive oxygen species or upregulation of other antioxidant systems.

There have been reports of increased SOD activity in erythrocytes in cataract patients compared to controls and the POLA study group showed an increased incidence of cortical cataract in patients with high SOD activity in erythrocytes [17–19]. Rajkumar et al. demonstrated increased SOD activity in lens capsule samples from cortical cataract patients and the activity declined gradually with age in all samples; the highest levels of SOD were found in samples from patients 50 years of age or younger [20]. However, conflicting data on SOD activity levels also exist and there are studies showing decreased SOD activity levels in erythrocytes, sera and lenses from cataract patients compared to controls [21–23]. The study size and size of the control group are limitations in our study and no difference in SOD activity was seen between cataract and controls, but few subjects in the control group renders this comparison difficult.

## Conclusion

In conclusion, these findings are in accordance with previous reports showing higher E2 concentration in men than in postmenopausal women. Although the present data does not provide hard proofs that oestradiol protects against cataract, the results are still supportive for the hypothesis that it is the decline in oestrogen for women in menopause that may be cataractogenic. However, the results do not support that a possible beneficial effect of oestrogen acts through an E2-mediated upregulation of SOD.

## Abbreviations

DHEA: Dehydroepiandrosterone; E2: Oestradiol;  
EDTA: Ethylenediaminetetraacetic acid; HRT: Hormonal replacement therapy;  
RIA: Radioimmunoassay; SHBG: Sex hormone-binding globulin;  
SOD: Superoxide dismutase

## Acknowledgements

This work was supported by grants from the Swedish Research Council (#2011-3132), Swedish government ("Agreement concerning research and education of doctors"; ALF-GBG-145921), Göteborg Medical Society, Marianne and Marcus Wallenberg Foundation, Dr Reinhard Marcuses Foundation, Konung Gustaf Vs och Drottning Victorias Frimurarestiftelse, Hjalmar Svensson Foundation, Greta Andersson Foundation, Herman Svensson Foundation, Ögonfonden, De Blindas Vänner and Kronprinsessan Margaretas Arbetsnämnd för Synskadade.

## Funding

This work was supported by grants from the Swedish Research Council (#2011-3132), Swedish government ("Agreement concerning research and

education of doctors"; ALF-GBG-145921), Göteborg Medical Society, Marianne and Marcus Wallenberg Foundation, Dr Reinhard Marcus Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjalmar Svensson Foundation, Greta Andersson Foundation, Herman Svensson Foundation, Ögonfonden, De Blindas Vänner and Kronprinsessan Margaretas Arbetsnämnd för Synskadade.

#### Availability of data and materials

Data can be shared upon request. Contact corresponding author: dragana.skiljic@gu.se.

#### Authors' contributions

DS carried out biochemical analysis and wrote the first draft of the manuscript and was responsible for coordination of the study, collection of data and interpretation of results. SN performed the statistical analysis and was responsible for data analysis and interpretation of results. AP, J-OK and AB were involved in interpretation of results and writing of manuscript. LK carried out the clinical examinations, collected data and was involved in interpretation of results and writing of manuscript. MZ carried out the clinical examinations, participated in interpretation of results, writing of manuscript, design and coordination of the study. All authors have read and approved the final version of the manuscript.

#### Competing interests

The authors declare that they have no competing interests.

#### Consent for publication

Not applicable.

#### Ethics approval and consent to participate

The Regional Research Ethics Committee in Gothenburg approved the study; Dnr.784-10. Written informed consent was obtained from all patients and controls.

#### Author details

<sup>1</sup>Department of Clinical Neuroscience/Ophthalmology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. <sup>2</sup>Department of Ophthalmology, Sahlgrenska University Hospital, Mölndal, Sweden. <sup>3</sup>Department of Mathematical Statistics, Institute of Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden. <sup>4</sup>Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. <sup>5</sup>Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden.

Received: 11 June 2016 Accepted: 24 November 2016

Published online: 29 November 2016

#### References

- Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99(4):546–52.
- Lundstrom M, Stenevi U, Thorburn W. Gender and cataract surgery in Sweden 1992–1997. A retrospective observational study based on the Swedish National Cataract Register. *Acta Ophthalmol Scand*. 1999;77(2):204–8.
- Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains eye study. *Ophthalmology*. 1997;104(4):581–8.
- Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E, Hales AM. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. *Am J Epidemiol*. 2002;155(11):997–1006.
- Klein BE, Klein R, Ritter LL. Is there evidence of an estrogen effect on age-related lens opacities? The Beaver Dam Eye Study. *Arch Ophthalmol*. 1994; 112(1):85–91.
- Worzala K, Hiller R, Sperduto RD, Mutalik K, Murabito JM, Moskowitz M, D'Agostino RB, Wilson PW. Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. *Arch Intern Med*. 2001;161(11):1448–54.
- Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, Vina J. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFkappaB cascade. *Aging Cell*. 2005;4(3):113–8.
- Razmara A, Duckles SP, Krause DN, Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. *Brain Res*. 2007;1176:71–81.
- Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. *Circ Res*. 2003;93(2):170–7.
- Gottipati S, Cammarata PR. Mitochondrial superoxide dismutase activation with 17 beta-estradiol-treated human lens epithelial cells. *Mol Vis*. 2008;14: 898–905.
- Ankarberg-Lindgren C, Norjavaara E. A purification step prior to commercial sensitive immunoassay is necessary to achieve clinical usefulness when quantifying serum 17beta-estradiol in prepubertal children. *Eur J Endocrinol*. 2008;158(1):117–24.
- Simpson ER. Sources of estrogen and their importance. *J Steroid Biochem Mol Biol*. 2003;86(3–5):225–30.
- Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. *J Clin Endocrinol Metab*. 1998;83(7):2266–74.
- Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. *J Clin Endocrinol Metab*. 2000;85(1):219–23.
- Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, Fryzek J, Acquavella J, Schwartz KL. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. *Ann Epidemiol*. 2011;21(3):156–63.
- Zhang XH, Sun HM, Ji J, Zhang H, Ma WJ, Jin Z, Yuan JQ. Sex hormones and their receptors in patients with age-related cataract. *J Cataract Refract Surg*. 2003;29(1):71–7.
- Casado A, de La Torre R, Lopez-Fernandez E. Antioxidant enzyme levels in red blood cells from cataract patients. *Gerontology*. 2001;47(4):186–8.
- Delcourt C, Carriere I, Delage M, Descamps B, Cristol JP, Papoz L. Associations of cataract with antioxidant enzymes and other risk factors: the French Age-Related Eye Diseases (POLA) Prospective Study. *Ophthalmology*. 2003;110(12):2318–26.
- Virgolici B, Stoian I, Musculel C, Maracine M, Popescu L, Moraru C, Dinu V. Systemic redox modifications in senile cataract. *Rom J Intern Med*. 2009; 47(3):279–87.
- Rajkumar S, Praveen MR, Gajjar D, Vasavada AR, Alapure B, Patel D, Kapur S. Activity of superoxide dismutase isoenzymes in lens epithelial cells derived from different types of age-related cataract. *J Cataract Refract Surg*. 2008; 34(3):470–4.
- Donma O, Yorulmaz E, Pekel H, Suyugul N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. *Curr Eye Res*. 2002;25(1):9–16.
- Kaur J, Kukreja S, Kaur A, Malhotra N, Kaur R. The oxidative stress in cataract patients. *J Clin Diagn Res*. 2012;6(10):1629–32.
- Babizhayev MA. Mitochondria induce oxidative stress, generation of reactive oxygen species and redox state unbalance of the eye lens leading to human cataract formation: disruption of redox lens organization by phospholipid hydroperoxides as a common basis for cataract disease. *Cell Biochem Funct*. 2011;29(3):183–206.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
www.biomedcentral.com/submit

